Literature DB >> 17684478

Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice.

M A Steiner1, K Wanisch, K Monory, G Marsicano, E Borroni, H Bächli, F Holsboer, B Lutz, C T Wotjak.   

Abstract

Dysregulation of the endocannabinoid system is known to interfere with emotional processing of stressful events. Here, we studied the role of cannabinoid receptor type 1 (CB1) signaling in stress-coping behaviors using the forced swim test (FST) with repeated exposures. We compared effects of genetic inactivation with pharmacological blockade of CB1 receptors both in male and female mice. In addition, we investigated potential interactions of the endocannabinoid system with monoaminergic and neurotrophin systems of the brain. Naive CB1 receptor-deficient mice (CB1-/-) showed increased passive stress-coping behaviors as compared to wild-type littermates (CB1+/+) in the FST, independent of sex. These findings were partially reproduced in C57BL/6N animals and fully reproduced in female CB1+/+ mice by pharmacological blockade of CB1 receptors with the CB1 receptor antagonist SR141716. The specificity of SR141716 was confirmed in female CB1-/- mice, where it failed to affect behavioral performance. Sensitivity to the antidepressants desipramine and paroxetine was preserved, but slightly altered in female CB1-/- mice. There were no genotype differences between CB1+/+ and CB1-/- mice in monoamine oxidase A and B activities under basal conditions, nor in monoamine content of hippocampal tissue after FST exposure. mRNA expression of vesicular glutamate transporter type 1 was unaffected in CB1-/- mice, but mRNA expression of brain-derived neurotrophic factor (BDNF) was reduced in the hippocampus. Our results suggest that impaired CB1 receptor function promotes passive stress-coping behavior, which, at least in part, might relate to alterations in BDNF function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684478     DOI: 10.1038/sj.tpj.6500466

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  32 in total

Review 1.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

2.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

Review 3.  Endocannabinoid-mediated synaptic plasticity and addiction-related behavior.

Authors:  Nimish Sidhpura; Loren H Parsons
Journal:  Neuropharmacology       Date:  2011-06-12       Impact factor: 5.250

4.  Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions.

Authors:  Mathieu Lafourcade; Thomas Larrieu; Susana Mato; Anais Duffaud; Marja Sepers; Isabelle Matias; Veronique De Smedt-Peyrusse; Virginie F Labrousse; Lionel Bretillon; Carlos Matute; Rafael Rodríguez-Puertas; Sophie Layé; Olivier J Manzoni
Journal:  Nat Neurosci       Date:  2011-01-30       Impact factor: 24.884

Review 5.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 6.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

7.  Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides.

Authors:  K Yaragudri Vinod; Suham A Kassir; Basalingappa L Hungund; Thomas B Cooper; J John Mann; Victoria Arango
Journal:  J Psychiatr Res       Date:  2009-12-16       Impact factor: 4.791

Review 8.  The endocannabinoid system in obesity and type 2 diabetes.

Authors:  V Di Marzo
Journal:  Diabetologia       Date:  2008-06-18       Impact factor: 10.122

Review 9.  Treatment-resistant depression: are animal models of depression fit for purpose?

Authors:  Paul Willner; Catherine Belzung
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

10.  Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of fluoxetine resistance in mice.

Authors:  Elsa Isingrini; Vincent Camus; Anne-Marie Le Guisquet; Maryse Pingaud; Séverine Devers; Catherine Belzung
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.